I understand, from all of the presentations we've heard, that there's a lot of dialogue and communication between Health Canada and the manufacturers, whether they're brand name or generic. So there's a lot of communication between the two organizations, but I fail to see the connection between the communication between the joe on the sidewalk who has had an adverse reaction and Health Canada or the manufacturers. As far as I know from speaking with pharmacists, they're not sharing much information with too many people. They're not sharing it with the pharmacist down the street. They're not sharing it with the hospital down the street. They're not sharing it with too many people.
So we're looking at communication not between the manufacturers and Health Canada but between the end user and Health Canada.
Can you help us with that? Do you see the deficiencies that we see, or do you not see a deficiency there?